HDAC4 Reduction

A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration

Michal Mielcarek, Christian Landles, Andreas Weiss, Amyaouch Bradaia, Tamara Seredenina, Linda Inuabasi, Georgina F. Osborne, Kristian Wadel, Chrystelle Touller, Rachel Butler, Janette Robertson, Sophie A. Franklin, Donna L. Smith, Larry Park, Paul A. Marks, Erich E. Wanker, Eric N. Olson, Ruth Luthi-Carter, Herman van der Putten, Vahri Beaumont & 1 others Gillian P. Bates

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Histone deacetylase (HDAC) 4 is a transcriptional repressor that contains a glutamine-rich domain. We hypothesised that it may be involved in the molecular pathogenesis of Huntington's disease (HD), a protein-folding neurodegenerative disorder caused by an aggregation-prone polyglutamine expansion in the huntingtin protein. We found that HDAC4 associates with huntingtin in a polyglutamine-length-dependent manner and co-localises with cytoplasmic inclusions. We show that HDAC4 reduction delayed cytoplasmic aggregate formation, restored Bdnf transcript levels, and rescued neuronal and cortico-striatal synaptic function in HD mouse models. This was accompanied by an improvement in motor coordination, neurological phenotypes, and increased lifespan. Surprisingly, HDAC4 reduction had no effect on global transcriptional dysfunction and did not modulate nuclear huntingtin aggregation. Our results define a crucial role for the cytoplasmic aggregation process in the molecular pathology of HD. HDAC4 reduction presents a novel strategy for targeting huntingtin aggregation, which may be amenable to small-molecule therapeutics.

Original languageEnglish (US)
Article numbere1001717
JournalPLoS Biology
Volume11
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

cytoplasmic inclusions
histone deacetylase
protein folding
disease models
Huntington Disease
neurodegenerative diseases
protein aggregates
glutamine
Agglomeration
pathogenesis
Proteostasis Deficiencies
animal models
Corpus Striatum
phenotype
therapeutics
Histone Deacetylases
Molecular Pathology
Inclusion Bodies
Glutamine
Neurodegenerative Diseases

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)

Cite this

Mielcarek, M., Landles, C., Weiss, A., Bradaia, A., Seredenina, T., Inuabasi, L., ... Bates, G. P. (2013). HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration. PLoS Biology, 11(11), [e1001717]. https://doi.org/10.1371/journal.pbio.1001717

HDAC4 Reduction : A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration. / Mielcarek, Michal; Landles, Christian; Weiss, Andreas; Bradaia, Amyaouch; Seredenina, Tamara; Inuabasi, Linda; Osborne, Georgina F.; Wadel, Kristian; Touller, Chrystelle; Butler, Rachel; Robertson, Janette; Franklin, Sophie A.; Smith, Donna L.; Park, Larry; Marks, Paul A.; Wanker, Erich E.; Olson, Eric N.; Luthi-Carter, Ruth; van der Putten, Herman; Beaumont, Vahri; Bates, Gillian P.

In: PLoS Biology, Vol. 11, No. 11, e1001717, 11.2013.

Research output: Contribution to journalArticle

Mielcarek, M, Landles, C, Weiss, A, Bradaia, A, Seredenina, T, Inuabasi, L, Osborne, GF, Wadel, K, Touller, C, Butler, R, Robertson, J, Franklin, SA, Smith, DL, Park, L, Marks, PA, Wanker, EE, Olson, EN, Luthi-Carter, R, van der Putten, H, Beaumont, V & Bates, GP 2013, 'HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration', PLoS Biology, vol. 11, no. 11, e1001717. https://doi.org/10.1371/journal.pbio.1001717
Mielcarek, Michal ; Landles, Christian ; Weiss, Andreas ; Bradaia, Amyaouch ; Seredenina, Tamara ; Inuabasi, Linda ; Osborne, Georgina F. ; Wadel, Kristian ; Touller, Chrystelle ; Butler, Rachel ; Robertson, Janette ; Franklin, Sophie A. ; Smith, Donna L. ; Park, Larry ; Marks, Paul A. ; Wanker, Erich E. ; Olson, Eric N. ; Luthi-Carter, Ruth ; van der Putten, Herman ; Beaumont, Vahri ; Bates, Gillian P. / HDAC4 Reduction : A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration. In: PLoS Biology. 2013 ; Vol. 11, No. 11.
@article{f65bd33b0c17406db4c09760f2163288,
title = "HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration",
abstract = "Histone deacetylase (HDAC) 4 is a transcriptional repressor that contains a glutamine-rich domain. We hypothesised that it may be involved in the molecular pathogenesis of Huntington's disease (HD), a protein-folding neurodegenerative disorder caused by an aggregation-prone polyglutamine expansion in the huntingtin protein. We found that HDAC4 associates with huntingtin in a polyglutamine-length-dependent manner and co-localises with cytoplasmic inclusions. We show that HDAC4 reduction delayed cytoplasmic aggregate formation, restored Bdnf transcript levels, and rescued neuronal and cortico-striatal synaptic function in HD mouse models. This was accompanied by an improvement in motor coordination, neurological phenotypes, and increased lifespan. Surprisingly, HDAC4 reduction had no effect on global transcriptional dysfunction and did not modulate nuclear huntingtin aggregation. Our results define a crucial role for the cytoplasmic aggregation process in the molecular pathology of HD. HDAC4 reduction presents a novel strategy for targeting huntingtin aggregation, which may be amenable to small-molecule therapeutics.",
author = "Michal Mielcarek and Christian Landles and Andreas Weiss and Amyaouch Bradaia and Tamara Seredenina and Linda Inuabasi and Osborne, {Georgina F.} and Kristian Wadel and Chrystelle Touller and Rachel Butler and Janette Robertson and Franklin, {Sophie A.} and Smith, {Donna L.} and Larry Park and Marks, {Paul A.} and Wanker, {Erich E.} and Olson, {Eric N.} and Ruth Luthi-Carter and {van der Putten}, Herman and Vahri Beaumont and Bates, {Gillian P.}",
year = "2013",
month = "11",
doi = "10.1371/journal.pbio.1001717",
language = "English (US)",
volume = "11",
journal = "PLoS Biology",
issn = "1544-9173",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - HDAC4 Reduction

T2 - A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration

AU - Mielcarek, Michal

AU - Landles, Christian

AU - Weiss, Andreas

AU - Bradaia, Amyaouch

AU - Seredenina, Tamara

AU - Inuabasi, Linda

AU - Osborne, Georgina F.

AU - Wadel, Kristian

AU - Touller, Chrystelle

AU - Butler, Rachel

AU - Robertson, Janette

AU - Franklin, Sophie A.

AU - Smith, Donna L.

AU - Park, Larry

AU - Marks, Paul A.

AU - Wanker, Erich E.

AU - Olson, Eric N.

AU - Luthi-Carter, Ruth

AU - van der Putten, Herman

AU - Beaumont, Vahri

AU - Bates, Gillian P.

PY - 2013/11

Y1 - 2013/11

N2 - Histone deacetylase (HDAC) 4 is a transcriptional repressor that contains a glutamine-rich domain. We hypothesised that it may be involved in the molecular pathogenesis of Huntington's disease (HD), a protein-folding neurodegenerative disorder caused by an aggregation-prone polyglutamine expansion in the huntingtin protein. We found that HDAC4 associates with huntingtin in a polyglutamine-length-dependent manner and co-localises with cytoplasmic inclusions. We show that HDAC4 reduction delayed cytoplasmic aggregate formation, restored Bdnf transcript levels, and rescued neuronal and cortico-striatal synaptic function in HD mouse models. This was accompanied by an improvement in motor coordination, neurological phenotypes, and increased lifespan. Surprisingly, HDAC4 reduction had no effect on global transcriptional dysfunction and did not modulate nuclear huntingtin aggregation. Our results define a crucial role for the cytoplasmic aggregation process in the molecular pathology of HD. HDAC4 reduction presents a novel strategy for targeting huntingtin aggregation, which may be amenable to small-molecule therapeutics.

AB - Histone deacetylase (HDAC) 4 is a transcriptional repressor that contains a glutamine-rich domain. We hypothesised that it may be involved in the molecular pathogenesis of Huntington's disease (HD), a protein-folding neurodegenerative disorder caused by an aggregation-prone polyglutamine expansion in the huntingtin protein. We found that HDAC4 associates with huntingtin in a polyglutamine-length-dependent manner and co-localises with cytoplasmic inclusions. We show that HDAC4 reduction delayed cytoplasmic aggregate formation, restored Bdnf transcript levels, and rescued neuronal and cortico-striatal synaptic function in HD mouse models. This was accompanied by an improvement in motor coordination, neurological phenotypes, and increased lifespan. Surprisingly, HDAC4 reduction had no effect on global transcriptional dysfunction and did not modulate nuclear huntingtin aggregation. Our results define a crucial role for the cytoplasmic aggregation process in the molecular pathology of HD. HDAC4 reduction presents a novel strategy for targeting huntingtin aggregation, which may be amenable to small-molecule therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84889031644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889031644&partnerID=8YFLogxK

U2 - 10.1371/journal.pbio.1001717

DO - 10.1371/journal.pbio.1001717

M3 - Article

VL - 11

JO - PLoS Biology

JF - PLoS Biology

SN - 1544-9173

IS - 11

M1 - e1001717

ER -